S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
WVE · Wave Life Sciences, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
WAVE Life Sciences Ltd (WVE)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$3.38
-0.05
(-1.46%)
● At close: October 21 at 4:00:00 PM EDT
$3.37
+0.00
(+0.00%)
Overnight:
10:00:26 PM EDT
DAY'S RANGE
$3.38
$3.35
$3.46
52-WEEK RANGE
$3.38
$3.04
$21.73
What's happening
- WVE is down 1.46% today, trading at $3.38. — Live quote
- It's trading within 3% of its 52-week low ($3.04). (Finnhub fundamentals)
- Volume today (141,173) is well below its 3-month average of 3,134,410. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.34 actual vs. $-0.31 estimated (-8.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 13
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (22 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
WVE
-79.88%
vs S&P 500
-92.66%
1-YEAR RETURN
WVE
-56.21%
vs S&P 500
-70.77%
6-MONTH RETURN
WVE
-53.28%
3-MONTH RETURN
WVE
-40.93%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.34
Est. $-0.31
MISS -8.9%
2026-04-26 (Q1 2026)
$-0.13
Est. $-0.33
BEAT +60.7%
2026-01-26 (Q4 2025)
$-0.30
Est. $-0.27
MISS -10.0%
2025-10-26 (Q3 2025)
$-0.32
Est. $-0.30
MISS -6.2%
Valuation Measures & Ratios
Enterprise Value4$321.7M
Forward P/E5—
PEG Ratio6-0.11
Price / Sales (TTM1)10.55
Price / Book72.46
EV4 / Revenue4.92
EV4 / EBITDA—
Profit Margin-309.73%
Operating Margin-333.36%
Return on Equity (ROE8)-49.87%
Return on Assets (ROA9)-40.06%
Avg Volume (3M)3,134,410
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.19B | $1.45B | $154.1M | $132.1M | $163.3M |
| P/E | -5.94 | -8.20 | -0.72 | -0.69 | -0.94 |
| Price/Book | 2.62 | 2.84 | 1.24 | 0.95 | 0.95 |
| ROE | -44.05% | -34.64% | -171.00% | -137.90% | -100.78% |
| ROA | -35.78% | -30.38% | -88.23% | -76.10% | -60.05% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short18,556,315
Change from Prior Settlement+5.21%
% of Float—
Days to Cover (Short Ratio)5.70
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-07; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -73.9% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -309.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -56.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on WVE
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $38.2M | — | $8.7M | $9.2M | — | $19.7M | $12.5M |
| Operating income | -$73.8M | -$31.3M | -$56.4M | -$52.8M | -$49.8M | -$63.9M | -$35.0M | -$34.5M |
| Net income | -$69.4M | -$26.1M | -$53.9M | -$50.5M | -$46.9M | -$61.8M | -$32.9M | -$31.6M |
| EPS (diluted) | $-0.34 | $-0.13 | $-0.32 | $-0.31 | $-0.29 | $-0.47 | $-0.25 | $-0.24 |
| EPS (basic) | $-0.34 | $-0.13 | $-0.32 | $-0.31 | $-0.29 | $-0.47 | $-0.25 | $-0.24 |
| Operating margin | -$3.2K | -$82 | — | -$606 | -$543 | — | -$178 | -$275 |
| Net margin | -$3.1K | -$68 | — | -$580 | -$511 | — | -$167 | -$252 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $558.3M | $583.5M | $638.5M | $241.4M | $252.4M | $288.3M | $352.2M | $358.5M |
| Total liabilities | $104.8M | $71.8M | $112.3M | $109.0M | $105.2M | $108.7M | $134.8M | $209.0M |
| Stockholders' equity | $453.5M | $511.7M | $518.4M | $124.5M | $139.3M | $171.8M | $209.5M | $141.6M |
| Total current assets | $507.5M | $561.3M | $614.8M | $215.5M | $223.6M | $258.0M | $320.4M | $324.5M |
| Total current liabilities | $50.8M | $49.8M | $95.1M | $85.9M | $87.4M | $87.4M | $111.0M | $170.7M |
| Cash & equivalents | $368.0M | $544.6M | $602.1M | $196.2M | $208.5M | $243.1M | $302.1M | $310.9M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $888.0K | $0 | $1.3M | $10.0M | $1.6M | — | $1.4M | $0 |
| Other current assets | $3.9M | $3.5M | $3.1M | $2.6M | $6.8M | $6.8M | $7.3M | $3.0M |
| Property, plant & equipment | $6.8M | $7.1M | $7.4M | $8.2M | $9.0M | $9.6M | $10.1M | $10.9M |
| Other non-current assets | $667.0K | $386.0K | $16.0K | $22.0K | $728.0K | $448.0K | $55.0K | — |
| Accounts payable | $20.4M | $19.1M | $15.7M | $14.5M | $14.7M | $14.4M | $16.3M | $12.8M |
| Accrued liabilities | $5.2M | $4.9M | $7.3M | $4.6M | $3.2M | $1.7M | $4.6M | $2.8M |
| Deferred revenue (current) | $8.7M | $9.4M | $44.4M | $46.5M | $51.6M | $57.3M | $66.0M | $135.9M |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $1.63B | $1.63B | $1.62B | $1.22B | $1.19B | $1.18B | $1.18B | $1.14B |
| Retained earnings | -$1.42B | -$1.35B | -$1.33B | -$1.27B | -$1.22B | -$1.17B | -$1.12B | -$1.15B |
| Accumulated other comprehensive income (loss) | -$172.0K | -$254.0K | -$250.0K | -$190.0K | -$161.0K | -$204.0K | -$262.0K | -$159.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$53.6M | -$59.6M | -$33.8M | -$44.7M | -$46.0M | -$63.0M | -$43.6M | -$46.5M |
| Investing cash flow | -$123.5M | -$438.0K | $1.0K | -$248.0K | -$306.0K | -$165.0K | -$86.0K | -$383.0K |
| Financing cash flow | $330.0K | $2.5M | $439.7M | $32.7M | $11.7M | $4.2M | $35.0M | $203.7M |
| Free cash flow | -$54.5M | -$60.0M | -$33.8M | -$44.9M | -$46.3M | -$63.2M | -$43.7M | -$46.9M |
| Capital expenditures | $884.0K | $438.0K | -$1.0K | $248.0K | $306.0K | $165.0K | $86.0K | $383.0K |
| Share-based compensation | — | — | — | — | — | — | — | — |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | $888.0K | -$1.3M | -$8.7M | $8.4M | $1.6M | -$1.4M | $1.4M | -$1.3M |
| Change in accounts payable | $1.6M | $3.3M | $1.2M | $59.0K | $276.0K | -$2.1M | $3.5M | -$5.1M |
| Purchases of investments | $122.6M | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $42.7M | $108.3M | $113.3M | $3.6M | $41.0M |
| Operating income | -$215.4M | -$110.4M | -$68.0M | -$162.7M | -$127.0M |
| Net income | -$204.4M | -$97.0M | -$57.5M | -$161.8M | -$122.2M |
| EPS (diluted) | $-1.21 | $-0.70 | $-0.54 | $-2.05 | $-2.36 |
| EPS (basic) | $-1.21 | $-0.70 | $-0.54 | $-2.05 | $-2.36 |
| Operating margin | -$504 | -$102 | -$60 | -$4.5K | -$310 |
| Net margin | -$478 | -$90 | -$51 | -$4.4K | -$298 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $638.5M | $352.2M | $274.9M | $146.4M | $207.0M |
| Total liabilities | $112.3M | $134.8M | $227.4M | $183.6M | $166.6M |
| Stockholders' equity | $518.4M | $209.5M | $39.6M | -$45.1M | $32.5M |
| Total current assets | $614.8M | $320.4M | $235.4M | $98.5M | $162.6M |
| Total current liabilities | $95.1M | $111.0M | $186.4M | $71.5M | $64.2M |
| Cash & equivalents | $602.1M | $302.1M | $200.4M | $88.5M | $150.6M |
| Accounts receivable | $1.3M | $1.4M | $21.1M | — | — |
| Other current assets | $3.1M | $7.3M | $4.0M | $2.1M | $5.4M |
| Property, plant & equipment | $7.4M | $10.1M | $13.1M | $17.3M | $22.3M |
| Other non-current assets | $16.0K | $55.0K | $156.0K | — | — |
| Accounts payable | $15.7M | $16.3M | $12.8M | $16.9M | $7.3M |
| Accrued liabilities | $7.3M | $4.6M | $1.8M | $3.5M | $3.6M |
| Deferred revenue (current) | $44.4M | $66.0M | $150.1M | $31.6M | $37.1M |
| Other current liabilities | — | — | — | — | — |
| Other non-current liabilities | — | — | — | $190.0K | — |
| Common stock & paid-in capital | $1.62B | $1.18B | $935.4M | $802.8M | $749.9M |
| Retained earnings | -$1.33B | -$1.12B | -$1.02B | -$967.3M | -$805.5M |
| Accumulated other comprehensive income (loss) | -$250.0K | -$262.0K | -$124.0K | -$29.0K | $181.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$187.5M | -$151.0M | -$19.4M | -$127.8M | -$89.0M |
| Investing cash flow | -$718.0K | -$938.0K | -$1.1M | -$1.3M | -$560.0K |
| Financing cash flow | $488.2M | $253.9M | $132.5M | $67.2M | $55.8M |
| Free cash flow | -$188.2M | -$152.0M | -$20.5M | -$129.1M | -$89.6M |
| Capital expenditures | $718.0K | $938.0K | $1.1M | $1.4M | $560.0K |
| Share-based compensation | — | — | — | — | — |
| Deferred income taxes | $0 | $0 | $0 | — | — |
| Change in accounts receivable | -$146.0K | -$19.7M | $21.1M | — | -$30.0M |
| Change in accounts payable | -$561.0K | $3.4M | -$3.8M | $9.3M | -$6.6M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding WVE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-08 to 2026-10-05
Recent transactions
- Insiders have net sold 23,996 shares over the last 182 days, across 0 purchases and 4 sales.
- Most recent: RA CAPITAL MANAGEMENT, L.P. (Reporting person) — Grant / award of 10,700 shares on 2026-10-05.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)23,996 sh(4 txns)
Net Shares-23,996
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Reporting person | Grant / award | 2026-10-05 | 10,700 |
| Verdine Gregory L. | Reporting person | Grant / award | 2026-10-05 | 10,700 |
| Tan Aik Na | Reporting person | Grant / award | 2026-10-05 | 10,700 |
| TAKANASHI KEN | Reporting person | Grant / award | 2026-10-05 | 10,700 |
| CORRIGAN MARK | Reporting person | Grant / award | 2026-10-05 | 10,700 |
| Rawcliffe Adrian | Reporting person | Grant / award | 2026-10-05 | 10,700 |
| Wagner Heidi L | Reporting person | Grant / award | 2026-10-05 | 10,700 |
| HENRY CHRISTIAN O | Reporting person | Grant / award | 2026-10-05 | 10,700 |
| Francis Chris | See Remarks | Option exercise | 2026-02-26 | 17,900 |
| Moran Kyle | Chief Financial Officer | Open market sale | 2026-02-09 | 3,588 |
| BOLNO PAUL | President and CEO | Open market sale | 2026-02-09 | 10,480 |
| Vargeese Chandra | See Remarks | Open market sale | 2026-02-09 | 3,228 |
| GSK plc | 10% owner | Open market purchase | 2025-12-11 | 1,470,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-05 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Grant / award | 10,700 | $0.00 |
| 2026-10-05 | Verdine Gregory L. | Reporting person | Grant / award | 10,700 | $0.00 |
| 2026-10-05 | Tan Aik Na | Reporting person | Grant / award | 10,700 | $0.00 |
| 2026-10-05 | TAKANASHI KEN | Reporting person | Grant / award | 10,700 | $0.00 |
| 2026-10-05 | CORRIGAN MARK | Reporting person | Grant / award | 10,700 | $0.00 |
| 2026-10-05 | Rawcliffe Adrian | Reporting person | Grant / award | 10,700 | $0.00 |
| 2026-10-05 | Wagner Heidi L | Reporting person | Grant / award | 10,700 | $0.00 |
| 2026-10-05 | HENRY CHRISTIAN O | Reporting person | Grant / award | 10,700 | $0.00 |
| 2026-08-12 | Rawcliffe Adrian | Reporting person | Open market sale | 12,700 | $5.29 |
| 2026-08-11 | Wagner Heidi L | Reporting person | Option exercise | 7,000 | $5.97 |
| 2026-08-11 | Wagner Heidi L | Reporting person | Open market sale | 7,000 | $6.01 |
| 2026-08-11 | TAKANASHI KEN | Reporting person | Open market sale | 3,864 | $6.01 |
| 2026-08-11 | Tan Aik Na | Reporting person | Open market sale | 432 | $6.01 |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market purchase | 971,091 | $6.50 |
| 2026-03-27 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market purchase | 2,495,623 | $6.43 |
| 2026-03-26 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market purchase | 4,954,558 | $6.06 |
| 2026-03-26 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market purchase | 351,224 | $6.38 |
| 2026-03-23 | TAKANASHI KEN | Reporting person | Derivative conversion | 3,901,348 | $0.00 |
| 2026-02-26 | Francis Chris | See Remarks | Option exercise | 17,900 | $3.87 |
| 2026-02-26 | Francis Chris | See Remarks | Open market sale | 17,900 | $15.09 |
| 2026-02-26 | Francis Chris | See Remarks | Option exercise | 15,294 | $4.75 |
| 2026-02-26 | Francis Chris | See Remarks | Open market sale | 15,294 | $15.00 |
| 2026-02-09 | Moran Kyle | Chief Financial Officer | Open market sale | 3,588 | $13.45 |
| 2026-02-09 | BOLNO PAUL | President and CEO | Open market sale | 10,480 | $13.45 |
| 2026-02-09 | Francis Chris | See Remarks | Open market sale | 1,883 | $13.45 |
| 2026-02-09 | Vargeese Chandra | See Remarks | Open market sale | 3,228 | $13.45 |
| 2026-02-05 | Moran Kyle | Chief Financial Officer | Grant / award | 45,625 | $0.00 |
| 2026-02-05 | BOLNO PAUL | President and CEO | Grant / award | 165,000 | $0.00 |
| 2026-02-05 | Francis Chris | See Remarks | Grant / award | 38,750 | $0.00 |
| 2026-02-05 | Vargeese Chandra | See Remarks | Grant / award | 45,625 | $0.00 |
| 2026-01-02 | Francis Chris | See Remarks | Option exercise | 9,375 | $3.14 |
| 2026-01-02 | Francis Chris | See Remarks | Open market sale | 8,080 | $15.92 |
| 2026-01-02 | Francis Chris | See Remarks | Open market sale | 1,295 | $16.70 |
| 2025-12-11 | GSK plc | 10% owner | Open market purchase | 1,470,000 | $19.00 |
| 2025-12-08 | Rawcliffe Adrian | Reporting person | Option exercise | 42,000 | $5.97 |
| 2025-12-08 | Rawcliffe Adrian | Reporting person | Open market sale | 42,000 | $15.00 |
| 2025-12-08 | Wagner Heidi L | Reporting person | Option exercise | 7,000 | $5.97 |
| 2025-12-08 | Wagner Heidi L | Reporting person | Open market sale | 7,000 | $13.00 |
| 2025-12-08 | Wagner Heidi L | Reporting person | Option exercise | 7,000 | $5.97 |
| 2025-12-08 | Wagner Heidi L | Reporting person | Open market sale | 7,000 | $14.00 |
| 2025-12-08 | HENRY CHRISTIAN O | Reporting person | Open market sale | 6,445 | $12.75 |
| 2025-12-08 | HENRY CHRISTIAN O | Reporting person | Option exercise | 42,000 | $5.97 |
| 2025-12-08 | HENRY CHRISTIAN O | Reporting person | Open market sale | 42,000 | $12.75 |
| 2025-12-08 | HENRY CHRISTIAN O | Reporting person | Option exercise | 15,000 | $3.50 |
| 2025-12-08 | HENRY CHRISTIAN O | Reporting person | Open market sale | 15,000 | $14.07 |
| 2025-12-08 | HENRY CHRISTIAN O | Reporting person | Option exercise | 30,000 | $4.58 |
| 2025-12-08 | HENRY CHRISTIAN O | Reporting person | Open market sale | 30,000 | $18.02 |
| 2025-12-08 | Tan Aik Na | Reporting person | Open market sale | 7,494 | $12.75 |
| 2025-12-08 | Tan Aik Na | Reporting person | Open market sale | 7,494 | $15.00 |
| 2025-12-08 | Tan Aik Na | Reporting person | Option exercise | 32,230 | $5.37 |
| 2025-12-08 | Tan Aik Na | Reporting person | Open market sale | 15,000 | $12.75 |
| 2025-12-08 | Tan Aik Na | Reporting person | Open market sale | 17,230 | $15.00 |
| 2025-12-08 | Tan Aik Na | Reporting person | Option exercise | 45,000 | $4.58 |
| 2025-12-08 | Tan Aik Na | Reporting person | Open market sale | 20,000 | $12.75 |
| 2025-12-08 | Tan Aik Na | Reporting person | Open market sale | 25,000 | $15.00 |
| 2025-12-08 | Tan Aik Na | Reporting person | Option exercise | 21,000 | $3.50 |
| 2025-12-08 | Tan Aik Na | Reporting person | Open market sale | 21,000 | $12.75 |
| 2025-12-08 | Tan Aik Na | Reporting person | Option exercise | 21,000 | $5.97 |
| 2025-12-08 | Tan Aik Na | Reporting person | Open market sale | 21,000 | $12.75 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:14 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-11 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-11 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-11 | View on SEC.gov → |
Recent news
Headlines about WVE (Wave Life Sciences, Inc.). Links open the publisher — we don’t host full articles.
-
WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
Yahoo Finance · 2026-10-22 -
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Yahoo · 2026-10-21 -
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
Yahoo · 2026-10-21 -
Wave Life Sciences announces virtual Research Day as stock rises 8%
Traders Union · 2026-10-20 -
Wave Life Sciences, Inc. (WVE) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
Yahoo · 2026-10-20 -
Wave sets Research Day for November 4: Wave Life Sciences stock is valued at USD 624.6 million - ad-hoc-news.de
ad-hoc-news.de · 2026-10-20 -
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
Yahoo · 2026-10-19
No headlines in this category right now — try “All”.